Currently, there are 228.22M common shares owned by the public and among those 222.22M shares have been available to trade.
The company’s stock has a 5-day price change of 73.21% and 30.22% over the past three months. VXRT shares are trading 6.03% year to date (YTD), with the 12-month market performance down to -8.77% lower. It has a 12-month low price of $0.28 and touched a high of $1.07 over the same period. VXRT has an average intraday trading volume of 3.61 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 50.65%, 69.83%, and 12.02% respectively.
Institutional ownership of Vaxart Inc (NASDAQ: VXRT) shares accounts for 18.85% of the company’s 228.22M shares outstanding.
It has a market capitalization of $160.27M and a beta (3y monthly) value of 1.17. The earnings-per-share (ttm) stands at -$0.27. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.77% over the week and 9.88% over the month.
Analysts forecast that Vaxart Inc (VXRT) will achieve an EPS of -0.09 for the current quarter, -0.06 for the next quarter and -0.34 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.11 while analysts give the company a high EPS estimate of -0.11. Comparatively, EPS for the current quarter was -0.09 a year ago. Earnings per share for the fiscal year are expected to increase by 15.15%, and -35.71% over the next financial year. EPS should shrink at an annualized rate of -6.35% over the next five years, compared to 17.46% over the past 5-year period.
Looking at the support for the VXRT, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on August 15, 2024, with the firm’s price target at $4. Jefferies coverage for the Vaxart Inc (VXRT) stock in a research note released on December 29, 2021 offered a Buy rating with a price target of $12. Cantor Fitzgerald was of a view on November 02, 2021 that the stock is Overweight, while B. Riley Securities gave the stock Neutral rating on June 29, 2021, issuing a price target of $13- $9. Jefferies on their part issued Buy rating on June 24, 2021.
